Comparative Pharmacology
Head-to-head clinical analysis: AMICAR versus AMINOCAPROIC ACID IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMICAR versus AMINOCAPROIC ACID IN PLASTIC CONTAINER.
AMICAR vs AMINOCAPROIC ACID IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Aminocaproic acid is a lysine analog that binds to plasminogen and prevents its conversion to plasmin, thereby inhibiting fibrinolysis and stabilizing clots. It also inhibits plasmin directly at high doses.
4-5 g IV loading dose over 1 hour, followed by 1 g/hour IV continuous infusion for 8 hours or until bleeding controlled; oral: 5 g PO initially, then 1-1.25 g PO every hour as needed.
4-5 g IV over 1 hour followed by 1 g/h IV for 8 hours or until bleeding is controlled; max 30 g/24h.
None Documented
None Documented
Terminal elimination half-life: 2 hours (range 1-3.5 hours). After high doses or renal impairment, half-life may prolong (up to 5-10 hours).
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In end-stage renal disease, half-life may be prolonged to 7-10 hours.
Renal: >99% of absorbed dose excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Primarily renal (approximately 80-90% excreted unchanged in urine via glomerular filtration).
Category C
Category C
Antifibrinolytic
Antifibrinolytic